Veterinary Oncology Market Forecasts to 2034 – Global Analysis By Animal Type (Dogs, Cats, Horses, and Other Companion Animals), Cancer Type, Diagnosis, Treatment Type, Route of Administration, Therapy, End User, Distribution Channel, and By Geography
According to Stratistics MRC, the Global Veterinary Oncology Market is accounted for $1.9 billion in 2026 and is expected to reach $5.1 billion by 2034 growing at a CAGR of 12.6% during the forecast period. Veterinary oncology is a specialized branch of veterinary medicine focused on the diagnosis, treatment, and management of cancer in animals. The market encompasses diagnostic methods including imaging (X-ray, ultrasound, CT, MRI, PET), biopsy and histopathology, cytology, molecular diagnostics, immunohistochemistry, laboratory tests, and other diagnostic approaches. Treatment modalities include chemotherapy, surgery, radiation therapy, immunotherapy, targeted therapy, combination therapy, and palliative care. Growing pet ownership, increasing prevalence of cancer in aging animal populations, rising demand for advanced veterinary care, and technological advancements in diagnostic and treatment modalities are key drivers of market expansion across all regions.
Market Dynamics:
Driver:
Increasing pet ownership and aging animal populations
The rising global pet population and the growing number of aging animals susceptible to cancer are primary drivers for the veterinary oncology market. As veterinary care advances and pets live longer, the incidence of cancer in companion animals is increasing. Pet owners are increasingly seeking specialized oncology services to extend their pets' lives and improve quality of life. The humanization of pets has led to greater willingness to invest in advanced cancer diagnostics and treatments comparable to human healthcare. As awareness of veterinary oncology options expands and pet owners prioritize comprehensive care, demand for cancer diagnosis and treatment services continues growing across all regions.
Restraint:
High treatment costs and limited insurance coverage
The significant costs associated with veterinary oncology diagnosis and treatment and limited pet insurance coverage represent a major restraint for the market. Cancer treatment including surgery, chemotherapy, and radiation therapy can be prohibitively expensive for many pet owners. Limited pet insurance penetration in many regions leaves owners responsible for substantial out-of-pocket expenses. Veterinary practices may require significant investment in oncology equipment and specialized staff, affecting service availability. These cost barriers may limit access to advanced oncology care, particularly for lower-income pet owners and in developing regions with limited insurance options.
Opportunity:
Advancements in diagnostic imaging and molecular diagnostics
Continuous innovation in diagnostic imaging and molecular diagnostic technologies presents significant opportunities for veterinary oncology market expansion. Advanced imaging including CT, MRI, and PET enables precise tumor localization, staging, and treatment planning. Molecular diagnostics including genetic testing and liquid biopsies enable early detection and personalized treatment approaches. Immunohistochemistry enables tumor characterization for targeted therapy selection. Integration of AI in diagnostic imaging enhances interpretation accuracy. As diagnostic technologies become more accessible and affordable, early detection and precise treatment planning capture growing market share, enabling improved outcomes.
Threat:
Shortage of veterinary oncologists and specialists
The limited availability of board-certified veterinary oncologists and trained support staff poses significant threats to the veterinary oncology market. Veterinary oncology requires specialized training beyond general veterinary education. The shortage of specialists restricts service availability, particularly in underserved areas and smaller practices. Limited training programs may constrain workforce growth. Veterinary practices may struggle to recruit qualified oncologists to staff oncology services. This workforce shortage may limit service expansion and patient access, potentially affecting market growth and patient outcomes.
Covid-19 Impact:
The COVID-19 pandemic had a significant impact on the veterinary oncology market. Initial disruptions included reduced veterinary visits during lockdowns, with many oncology appointments postponed. Supply chain interruptions affected diagnostic and treatment supplies. However, pet adoption surged during the pandemic, expanding the pet population and creating new patients. Telemedicine enabled remote consultations and follow-up care. Pet owners prioritized pet health during the crisis. Post-pandemic, elevated pet ownership and continued focus on pet health have sustained demand for veterinary oncology services, with practices resuming and expanding oncology offerings.
The Imaging segment is expected to be the largest during the forecast period
The Imaging segment is expected to account for the largest market share during the forecast period, driven by the essential role of diagnostic imaging in cancer detection, staging, treatment planning, and monitoring across all oncology cases. Imaging modalities including X-ray, ultrasound, CT, MRI, and PET are fundamental to veterinary oncology practice. The segment benefits from established technology adoption, continuous innovation, and expanding availability across practice types. Imaging is often the first diagnostic step in suspected cancer cases and is essential for evaluating treatment response. With essential diagnostic role and broad adoption across practice settings, imaging maintains the largest diagnostic segment share throughout the forecast period.
The Combination Therapy segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the Combination Therapy segment is predicted to witness the highest growth rate, fueled by growing evidence of superior outcomes from multimodal treatment approaches and increasing adoption of integrated oncology protocols combining surgery, chemotherapy, radiation, and immunotherapy. Combination therapy offers improved survival rates and quality of life compared to single-modality treatment. The segment benefits from advances in understanding cancer biology and treatment interactions. Growing veterinary specialty centers offering comprehensive oncology services drive adoption. As treatment protocols evolve and integrated care becomes standard, combination therapy delivers the fastest treatment segment growth.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share, supported by high pet ownership rates, strong spending on veterinary care, and advanced veterinary oncology infrastructure. The United States leads regional market growth with substantial investment in specialty veterinary services. Availability of board-certified veterinary oncologists and advanced treatment facilities supports service provision. High awareness of oncology treatment options among pet owners drives demand. Established pet insurance and financing options enable treatment access. With high pet spending and advanced oncology infrastructure, North America maintains its dominant market position.
Region with highest CAGR:
Over the forecast period, the Asia-Pacific region is anticipated to exhibit the highest CAGR, driven by rising pet ownership, increasing disposable incomes, and growing awareness of advanced veterinary oncology services across countries including China, India, Japan, and Australia. The region's rapidly growing pet population and expanding middle class create substantial demand for veterinary specialty services. Veterinary practice modernization and technology adoption are accelerating. Increasing investment in veterinary education and specialist training expands oncology capacity. Growing awareness of cancer treatment options among pet owners drives demand. As veterinary healthcare develops, Asia Pacific delivers the fastest veterinary oncology market growth globally.
Key players in the market
Some of the key players in Veterinary Oncology Market include Zoetis Inc., Elanco Animal Health Incorporated, Merck Animal Health, Boehringer Ingelheim Animal Health, Virbac S.A., Dechra Pharmaceuticals PLC, IDEXX Laboratories, Inc., Antech Diagnostics, Inc., VolitionRx Limited, Torigen Pharmaceuticals Inc., PetCure Oncology, Varian Medical Systems, Inc., Accuray Incorporated, FidoCure (One Health Company), ImpriMed, Inc., and Regeneus Ltd.
Key Developments:
In March 2026, Torigen Pharmaceuticals detailed the regulatory evolution of its point-of-care autologous cancer vaccine, VimClara, moving to a 9 CFR 107.1 in-clinic preparation kit classification that allows veterinarians to create personalized immunotherapies from excised tumor tissue in roughly 40 minutes.
In February 2026, Zoetis completed the acquisition of Veterinary Pathology Group (VPG) to expand its multi-specialty diagnostic services, enhancing specialized oncology pathology support and fast-turnaround diagnostic insights for veterinary practices.
In January 2026, VolitionRx announced breakthrough clinical results for its Nu.Q® Vet Feline assay, demonstrating over 80% sensitivity at 100% specificity for detecting feline lymphoma, paving the way for the world's first blood-based liquid biopsy test for cat cancer.
In September 2025, IDEXX Laboratories presented clinical data at the Veterinary Cancer Society Annual Conference highlighting its IDEXX Cancer Dx™ blood test, which detected circulating biomarkers for canine lymphoma up to 6 to 8 months prior to the onset of clinical signs.
Animal Types Covered:
All the customers of this report will be entitled to receive one of the following free customization options:
Market Dynamics:
Driver:
Increasing pet ownership and aging animal populations
The rising global pet population and the growing number of aging animals susceptible to cancer are primary drivers for the veterinary oncology market. As veterinary care advances and pets live longer, the incidence of cancer in companion animals is increasing. Pet owners are increasingly seeking specialized oncology services to extend their pets' lives and improve quality of life. The humanization of pets has led to greater willingness to invest in advanced cancer diagnostics and treatments comparable to human healthcare. As awareness of veterinary oncology options expands and pet owners prioritize comprehensive care, demand for cancer diagnosis and treatment services continues growing across all regions.
Restraint:
High treatment costs and limited insurance coverage
The significant costs associated with veterinary oncology diagnosis and treatment and limited pet insurance coverage represent a major restraint for the market. Cancer treatment including surgery, chemotherapy, and radiation therapy can be prohibitively expensive for many pet owners. Limited pet insurance penetration in many regions leaves owners responsible for substantial out-of-pocket expenses. Veterinary practices may require significant investment in oncology equipment and specialized staff, affecting service availability. These cost barriers may limit access to advanced oncology care, particularly for lower-income pet owners and in developing regions with limited insurance options.
Opportunity:
Advancements in diagnostic imaging and molecular diagnostics
Continuous innovation in diagnostic imaging and molecular diagnostic technologies presents significant opportunities for veterinary oncology market expansion. Advanced imaging including CT, MRI, and PET enables precise tumor localization, staging, and treatment planning. Molecular diagnostics including genetic testing and liquid biopsies enable early detection and personalized treatment approaches. Immunohistochemistry enables tumor characterization for targeted therapy selection. Integration of AI in diagnostic imaging enhances interpretation accuracy. As diagnostic technologies become more accessible and affordable, early detection and precise treatment planning capture growing market share, enabling improved outcomes.
Threat:
Shortage of veterinary oncologists and specialists
The limited availability of board-certified veterinary oncologists and trained support staff poses significant threats to the veterinary oncology market. Veterinary oncology requires specialized training beyond general veterinary education. The shortage of specialists restricts service availability, particularly in underserved areas and smaller practices. Limited training programs may constrain workforce growth. Veterinary practices may struggle to recruit qualified oncologists to staff oncology services. This workforce shortage may limit service expansion and patient access, potentially affecting market growth and patient outcomes.
Covid-19 Impact:
The COVID-19 pandemic had a significant impact on the veterinary oncology market. Initial disruptions included reduced veterinary visits during lockdowns, with many oncology appointments postponed. Supply chain interruptions affected diagnostic and treatment supplies. However, pet adoption surged during the pandemic, expanding the pet population and creating new patients. Telemedicine enabled remote consultations and follow-up care. Pet owners prioritized pet health during the crisis. Post-pandemic, elevated pet ownership and continued focus on pet health have sustained demand for veterinary oncology services, with practices resuming and expanding oncology offerings.
The Imaging segment is expected to be the largest during the forecast period
The Imaging segment is expected to account for the largest market share during the forecast period, driven by the essential role of diagnostic imaging in cancer detection, staging, treatment planning, and monitoring across all oncology cases. Imaging modalities including X-ray, ultrasound, CT, MRI, and PET are fundamental to veterinary oncology practice. The segment benefits from established technology adoption, continuous innovation, and expanding availability across practice types. Imaging is often the first diagnostic step in suspected cancer cases and is essential for evaluating treatment response. With essential diagnostic role and broad adoption across practice settings, imaging maintains the largest diagnostic segment share throughout the forecast period.
The Combination Therapy segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the Combination Therapy segment is predicted to witness the highest growth rate, fueled by growing evidence of superior outcomes from multimodal treatment approaches and increasing adoption of integrated oncology protocols combining surgery, chemotherapy, radiation, and immunotherapy. Combination therapy offers improved survival rates and quality of life compared to single-modality treatment. The segment benefits from advances in understanding cancer biology and treatment interactions. Growing veterinary specialty centers offering comprehensive oncology services drive adoption. As treatment protocols evolve and integrated care becomes standard, combination therapy delivers the fastest treatment segment growth.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share, supported by high pet ownership rates, strong spending on veterinary care, and advanced veterinary oncology infrastructure. The United States leads regional market growth with substantial investment in specialty veterinary services. Availability of board-certified veterinary oncologists and advanced treatment facilities supports service provision. High awareness of oncology treatment options among pet owners drives demand. Established pet insurance and financing options enable treatment access. With high pet spending and advanced oncology infrastructure, North America maintains its dominant market position.
Region with highest CAGR:
Over the forecast period, the Asia-Pacific region is anticipated to exhibit the highest CAGR, driven by rising pet ownership, increasing disposable incomes, and growing awareness of advanced veterinary oncology services across countries including China, India, Japan, and Australia. The region's rapidly growing pet population and expanding middle class create substantial demand for veterinary specialty services. Veterinary practice modernization and technology adoption are accelerating. Increasing investment in veterinary education and specialist training expands oncology capacity. Growing awareness of cancer treatment options among pet owners drives demand. As veterinary healthcare develops, Asia Pacific delivers the fastest veterinary oncology market growth globally.
Key players in the market
Some of the key players in Veterinary Oncology Market include Zoetis Inc., Elanco Animal Health Incorporated, Merck Animal Health, Boehringer Ingelheim Animal Health, Virbac S.A., Dechra Pharmaceuticals PLC, IDEXX Laboratories, Inc., Antech Diagnostics, Inc., VolitionRx Limited, Torigen Pharmaceuticals Inc., PetCure Oncology, Varian Medical Systems, Inc., Accuray Incorporated, FidoCure (One Health Company), ImpriMed, Inc., and Regeneus Ltd.
Key Developments:
In March 2026, Torigen Pharmaceuticals detailed the regulatory evolution of its point-of-care autologous cancer vaccine, VimClara, moving to a 9 CFR 107.1 in-clinic preparation kit classification that allows veterinarians to create personalized immunotherapies from excised tumor tissue in roughly 40 minutes.
In February 2026, Zoetis completed the acquisition of Veterinary Pathology Group (VPG) to expand its multi-specialty diagnostic services, enhancing specialized oncology pathology support and fast-turnaround diagnostic insights for veterinary practices.
In January 2026, VolitionRx announced breakthrough clinical results for its Nu.Q® Vet Feline assay, demonstrating over 80% sensitivity at 100% specificity for detecting feline lymphoma, paving the way for the world's first blood-based liquid biopsy test for cat cancer.
In September 2025, IDEXX Laboratories presented clinical data at the Veterinary Cancer Society Annual Conference highlighting its IDEXX Cancer Dx™ blood test, which detected circulating biomarkers for canine lymphoma up to 6 to 8 months prior to the onset of clinical signs.
Animal Types Covered:
- Dogs
- Cats
- Horses
- Other Companion Animals
- Lymphoma
- Mast Cell Cancer
- Osteosarcoma
- Mammary Gland Tumors
- Melanoma
- Soft Tissue Sarcoma
- Hemangiosarcoma
- Squamous Cell Carcinoma
- Transitional Cell Carcinoma
- Other Cancer Types
- Imaging
- Biopsy and Histopathology
- Cytology
- Molecular Diagnostics
- Immunohistochemistry
- Laboratory Tests
- Other Diagnostic Methods
- Chemotherapy
- Surgery
- Radiation Therapy
- Immunotherapy
- Targeted Therapy
- Combination Therapy
- Palliative Care
- Oral
- Injectable
- Topical
- Drug Therapy
- Surgical Oncology
- Radiation Oncology
- Precision Oncology
- Veterinary Hospitals
- Veterinary Clinics
- Veterinary Diagnostic Laboratories
- Veterinary Academic and Research Institutes
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Direct Sales
- North America
- United States
- Canada
- Mexico
- Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Netherlands
- Belgium
- Sweden
- Switzerland
- Poland
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Vietnam
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Colombia
- Chile
- Peru
- Rest of South America
- Rest of the World (RoW)
- Middle East
- Saudi Arabia
- United Arab Emirates
- Qatar
- Israel
- Rest of Middle East
- Africa
- South Africa
- Egypt
- Morocco
- Rest of Africa
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
1 EXECUTIVE SUMMARY
1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations
2 RESEARCH FRAMEWORK
2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
2.4.1 Data Collection (Primary and Secondary)
2.4.2 Data Modeling and Estimation Techniques
2.4.3 Data Validation and Triangulation
2.4.4 Analytical and Forecasting Approach
3 MARKET DYNAMICS AND TREND ANALYSIS
3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook
4 COMPETITIVE AND STRATEGIC ASSESSMENT
4.1 Porter's Five Forces Analysis
4.1.1 Supplier Bargaining Power
4.1.2 Buyer Bargaining Power
4.1.3 Threat of Substitutes
4.1.4 Threat of New Entrants
4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison
5 GLOBAL VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE
5.1 Dogs
5.2 Cats
5.3 Horses
5.4 Other Companion Animals
6 GLOBAL VETERINARY ONCOLOGY MARKET, BY CANCER TYPE
6.1 Lymphoma
6.2 Mast Cell Cancer
6.3 Osteosarcoma
6.4 Mammary Gland Tumors
6.5 Melanoma
6.6 Soft Tissue Sarcoma
6.7 Hemangiosarcoma
6.8 Squamous Cell Carcinoma
6.9 Transitional Cell Carcinoma
6.10 Other Cancer Types
7 GLOBAL VETERINARY ONCOLOGY MARKET, BY DIAGNOSIS
7.1 Imaging
7.1.1 X-ray
7.1.2 Ultrasound
7.1.3 Computed Tomography (CT)
7.1.4 Magnetic Resonance Imaging (MRI)
7.1.5 Positron Emission Tomography (PET)
7.2 Biopsy and Histopathology
7.3 Cytology
7.4 Molecular Diagnostics
7.5 Immunohistochemistry
7.6 Laboratory Tests
7.7 Other Diagnostic Methods
8 GLOBAL VETERINARY ONCOLOGY MARKET, BY TREATMENT TYPE
8.1 Chemotherapy
8.2 Surgery
8.3 Radiation Therapy
8.4 Immunotherapy
8.5 Targeted Therapy
8.6 Combination Therapy
8.7 Palliative Care
9 GLOBAL VETERINARY ONCOLOGY MARKET, BY ROUTE OF ADMINISTRATION
9.1 Oral
9.2 Injectable
9.3 Topical
10 GLOBAL VETERINARY ONCOLOGY MARKET, BY THERAPY
10.1 Drug Therapy
10.2 Surgical Oncology
10.3 Radiation Oncology
10.4 Precision Oncology
11 GLOBAL VETERINARY ONCOLOGY MARKET, BY END USER
11.1 Veterinary Hospitals
11.2 Veterinary Clinics
11.3 Veterinary Diagnostic Laboratories
11.4 Veterinary Academic and Research Institutes
12 GLOBAL VETERINARY ONCOLOGY MARKET, BY DISTRIBUTION CHANNEL
12.1 Hospital Pharmacies
12.2 Retail Pharmacies
12.3 Online Pharmacies
12.4 Direct Sales
13 GLOBAL VETERINARY ONCOLOGY MARKET, BY GEOGRAPHY
13.1 North America
13.1.1 United States
13.1.2 Canada
13.1.3 Mexico
13.2 Europe
13.2.1 United Kingdom
13.2.2 Germany
13.2.3 France
13.2.4 Italy
13.2.5 Spain
13.2.6 Netherlands
13.2.7 Belgium
13.2.8 Sweden
13.2.9 Switzerland
13.2.10 Poland
13.2.11 Rest of Europe
13.3 Asia Pacific
13.3.1 China
13.3.2 Japan
13.3.3 India
13.3.4 South Korea
13.3.5 Australia
13.3.6 Indonesia
13.3.7 Thailand
13.3.8 Malaysia
13.3.9 Singapore
13.3.10 Vietnam
13.3.11 Rest of Asia Pacific
13.4 South America
13.4.1 Brazil
13.4.2 Argentina
13.4.3 Colombia
13.4.4 Chile
13.4.5 Peru
13.4.6 Rest of South America
13.5 Rest of the World (RoW)
13.5.1 Middle East
13.5.1.1 Saudi Arabia
13.5.1.2 United Arab Emirates
13.5.1.3 Qatar
13.5.1.4 Israel
13.5.1.5 Rest of Middle East
13.5.2 Africa
13.5.2.1 South Africa
13.5.2.2 Egypt
13.5.2.3 Morocco
13.5.2.4 Rest of Africa
14 STRATEGIC MARKET INTELLIGENCE
14.1 Industry Value Network and Supply Chain Assessment
14.2 White-Space and Opportunity Mapping
14.3 Product Evolution and Market Life Cycle Analysis
14.4 Channel, Distributor, and Go-to-Market Assessment
15 INDUSTRY DEVELOPMENTS AND STRATEGIC INITIATIVES
15.1 Mergers and Acquisitions
15.2 Partnerships, Alliances, and Joint Ventures
15.3 New Product Launches and Regulatory Approvals
15.4 Capacity Expansion and Investments
15.5 Other Strategic Initiatives
16 COMPANY PROFILES
16.1 Zoetis Inc.
16.2 Elanco Animal Health Incorporated
16.3 Merck Animal Health
16.4 Boehringer Ingelheim Animal Health
16.5 Virbac S.A.
16.6 Dechra Pharmaceuticals PLC
16.7 IDEXX Laboratories, Inc.
16.8 Antech Diagnostics, Inc.
16.9 VolitionRx Limited
16.10 Torigen Pharmaceuticals Inc.
16.11 PetCure Oncology
16.12 Varian Medical Systems, Inc.
16.13 Accuray Incorporated
16.14 FidoCure (One Health Company)
16.15 ImpriMed, Inc.
16.16 Regeneus Ltd.
1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations
2 RESEARCH FRAMEWORK
2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
2.4.1 Data Collection (Primary and Secondary)
2.4.2 Data Modeling and Estimation Techniques
2.4.3 Data Validation and Triangulation
2.4.4 Analytical and Forecasting Approach
3 MARKET DYNAMICS AND TREND ANALYSIS
3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook
4 COMPETITIVE AND STRATEGIC ASSESSMENT
4.1 Porter's Five Forces Analysis
4.1.1 Supplier Bargaining Power
4.1.2 Buyer Bargaining Power
4.1.3 Threat of Substitutes
4.1.4 Threat of New Entrants
4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison
5 GLOBAL VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE
5.1 Dogs
5.2 Cats
5.3 Horses
5.4 Other Companion Animals
6 GLOBAL VETERINARY ONCOLOGY MARKET, BY CANCER TYPE
6.1 Lymphoma
6.2 Mast Cell Cancer
6.3 Osteosarcoma
6.4 Mammary Gland Tumors
6.5 Melanoma
6.6 Soft Tissue Sarcoma
6.7 Hemangiosarcoma
6.8 Squamous Cell Carcinoma
6.9 Transitional Cell Carcinoma
6.10 Other Cancer Types
7 GLOBAL VETERINARY ONCOLOGY MARKET, BY DIAGNOSIS
7.1 Imaging
7.1.1 X-ray
7.1.2 Ultrasound
7.1.3 Computed Tomography (CT)
7.1.4 Magnetic Resonance Imaging (MRI)
7.1.5 Positron Emission Tomography (PET)
7.2 Biopsy and Histopathology
7.3 Cytology
7.4 Molecular Diagnostics
7.5 Immunohistochemistry
7.6 Laboratory Tests
7.7 Other Diagnostic Methods
8 GLOBAL VETERINARY ONCOLOGY MARKET, BY TREATMENT TYPE
8.1 Chemotherapy
8.2 Surgery
8.3 Radiation Therapy
8.4 Immunotherapy
8.5 Targeted Therapy
8.6 Combination Therapy
8.7 Palliative Care
9 GLOBAL VETERINARY ONCOLOGY MARKET, BY ROUTE OF ADMINISTRATION
9.1 Oral
9.2 Injectable
9.3 Topical
10 GLOBAL VETERINARY ONCOLOGY MARKET, BY THERAPY
10.1 Drug Therapy
10.2 Surgical Oncology
10.3 Radiation Oncology
10.4 Precision Oncology
11 GLOBAL VETERINARY ONCOLOGY MARKET, BY END USER
11.1 Veterinary Hospitals
11.2 Veterinary Clinics
11.3 Veterinary Diagnostic Laboratories
11.4 Veterinary Academic and Research Institutes
12 GLOBAL VETERINARY ONCOLOGY MARKET, BY DISTRIBUTION CHANNEL
12.1 Hospital Pharmacies
12.2 Retail Pharmacies
12.3 Online Pharmacies
12.4 Direct Sales
13 GLOBAL VETERINARY ONCOLOGY MARKET, BY GEOGRAPHY
13.1 North America
13.1.1 United States
13.1.2 Canada
13.1.3 Mexico
13.2 Europe
13.2.1 United Kingdom
13.2.2 Germany
13.2.3 France
13.2.4 Italy
13.2.5 Spain
13.2.6 Netherlands
13.2.7 Belgium
13.2.8 Sweden
13.2.9 Switzerland
13.2.10 Poland
13.2.11 Rest of Europe
13.3 Asia Pacific
13.3.1 China
13.3.2 Japan
13.3.3 India
13.3.4 South Korea
13.3.5 Australia
13.3.6 Indonesia
13.3.7 Thailand
13.3.8 Malaysia
13.3.9 Singapore
13.3.10 Vietnam
13.3.11 Rest of Asia Pacific
13.4 South America
13.4.1 Brazil
13.4.2 Argentina
13.4.3 Colombia
13.4.4 Chile
13.4.5 Peru
13.4.6 Rest of South America
13.5 Rest of the World (RoW)
13.5.1 Middle East
13.5.1.1 Saudi Arabia
13.5.1.2 United Arab Emirates
13.5.1.3 Qatar
13.5.1.4 Israel
13.5.1.5 Rest of Middle East
13.5.2 Africa
13.5.2.1 South Africa
13.5.2.2 Egypt
13.5.2.3 Morocco
13.5.2.4 Rest of Africa
14 STRATEGIC MARKET INTELLIGENCE
14.1 Industry Value Network and Supply Chain Assessment
14.2 White-Space and Opportunity Mapping
14.3 Product Evolution and Market Life Cycle Analysis
14.4 Channel, Distributor, and Go-to-Market Assessment
15 INDUSTRY DEVELOPMENTS AND STRATEGIC INITIATIVES
15.1 Mergers and Acquisitions
15.2 Partnerships, Alliances, and Joint Ventures
15.3 New Product Launches and Regulatory Approvals
15.4 Capacity Expansion and Investments
15.5 Other Strategic Initiatives
16 COMPANY PROFILES
16.1 Zoetis Inc.
16.2 Elanco Animal Health Incorporated
16.3 Merck Animal Health
16.4 Boehringer Ingelheim Animal Health
16.5 Virbac S.A.
16.6 Dechra Pharmaceuticals PLC
16.7 IDEXX Laboratories, Inc.
16.8 Antech Diagnostics, Inc.
16.9 VolitionRx Limited
16.10 Torigen Pharmaceuticals Inc.
16.11 PetCure Oncology
16.12 Varian Medical Systems, Inc.
16.13 Accuray Incorporated
16.14 FidoCure (One Health Company)
16.15 ImpriMed, Inc.
16.16 Regeneus Ltd.
LIST OF TABLES
Table 1 Global Veterinary Oncology Market Outlook, By Region (2023–2034) ($MN)
Table 2 Global Veterinary Oncology Market Outlook, By Animal Type (2023–2034) ($MN)
Table 3 Global Veterinary Oncology Market Outlook, By Dogs (2023–2034) ($MN)
Table 4 Global Veterinary Oncology Market Outlook, By Cats (2023–2034) ($MN)
Table 5 Global Veterinary Oncology Market Outlook, By Horses (2023–2034) ($MN)
Table 6 Global Veterinary Oncology Market Outlook, By Other Companion Animals (2023–2034) ($MN)
Table 7 Global Veterinary Oncology Market Outlook, By Cancer Type (2023–2034) ($MN)
Table 8 Global Veterinary Oncology Market Outlook, By Lymphoma (2023–2034) ($MN)
Table 9 Global Veterinary Oncology Market Outlook, By Mast Cell Cancer (2023–2034) ($MN)
Table 10 Global Veterinary Oncology Market Outlook, By Osteosarcoma (2023–2034) ($MN)
Table 11 Global Veterinary Oncology Market Outlook, By Mammary Gland Tumors (2023–2034) ($MN)
Table 12 Global Veterinary Oncology Market Outlook, By Melanoma (2023–2034) ($MN)
Table 13 Global Veterinary Oncology Market Outlook, By Soft Tissue Sarcoma (2023–2034) ($MN)
Table 14 Global Veterinary Oncology Market Outlook, By Hemangiosarcoma (2023–2034) ($MN)
Table 15 Global Veterinary Oncology Market Outlook, By Squamous Cell Carcinoma (2023–2034) ($MN)
Table 16 Global Veterinary Oncology Market Outlook, By Transitional Cell Carcinoma (2023–2034) ($MN)
Table 17 Global Veterinary Oncology Market Outlook, By Other Cancer Types (2023–2034) ($MN)
Table 18 Global Veterinary Oncology Market Outlook, By Diagnosis (2023–2034) ($MN)
Table 19 Global Veterinary Oncology Market Outlook, By Imaging (2023–2034) ($MN)
Table 20 Global Veterinary Oncology Market Outlook, By X-ray (2023–2034) ($MN)
Table 21 Global Veterinary Oncology Market Outlook, By Ultrasound (2023–2034) ($MN)
Table 22 Global Veterinary Oncology Market Outlook, By Computed Tomography (CT) (2023–2034) ($MN)
Table 23 Global Veterinary Oncology Market Outlook, By Magnetic Resonance Imaging (MRI) (2023–2034) ($MN)
Table 24 Global Veterinary Oncology Market Outlook, By Positron Emission Tomography (PET) (2023–2034) ($MN)
Table 25 Global Veterinary Oncology Market Outlook, By Biopsy and Histopathology (2023–2034) ($MN)
Table 26 Global Veterinary Oncology Market Outlook, By Cytology (2023–2034) ($MN)
Table 27 Global Veterinary Oncology Market Outlook, By Molecular Diagnostics (2023–2034) ($MN)
Table 28 Global Veterinary Oncology Market Outlook, By Immunohistochemistry (2023–2034) ($MN)
Table 29 Global Veterinary Oncology Market Outlook, By Laboratory Tests (2023–2034) ($MN)
Table 30 Global Veterinary Oncology Market Outlook, By Other Diagnostic Methods (2023–2034) ($MN)
Table 31 Global Veterinary Oncology Market Outlook, By Treatment Type (2023–2034) ($MN)
Table 32 Global Veterinary Oncology Market Outlook, By Chemotherapy (2023–2034) ($MN)
Table 33 Global Veterinary Oncology Market Outlook, By Surgery (2023–2034) ($MN)
Table 34 Global Veterinary Oncology Market Outlook, By Radiation Therapy (2023–2034) ($MN)
Table 35 Global Veterinary Oncology Market Outlook, By Immunotherapy (2023–2034) ($MN)
Table 36 Global Veterinary Oncology Market Outlook, By Targeted Therapy (2023–2034) ($MN)
Table 37 Global Veterinary Oncology Market Outlook, By Combination Therapy (2023–2034) ($MN)
Table 38 Global Veterinary Oncology Market Outlook, By Palliative Care (2023–2034) ($MN)
Table 39 Global Veterinary Oncology Market Outlook, By Route of Administration (2023–2034) ($MN)
Table 40 Global Veterinary Oncology Market Outlook, By Oral (2023–2034) ($MN)
Table 41 Global Veterinary Oncology Market Outlook, By Injectable (2023–2034) ($MN)
Table 42 Global Veterinary Oncology Market Outlook, By Topical (2023–2034) ($MN)
Table 43 Global Veterinary Oncology Market Outlook, By Therapy (2023–2034) ($MN)
Table 44 Global Veterinary Oncology Market Outlook, By Drug Therapy (2023–2034) ($MN)
Table 45 Global Veterinary Oncology Market Outlook, By Surgical Oncology (2023–2034) ($MN)
Table 46 Global Veterinary Oncology Market Outlook, By Radiation Oncology (2023–2034) ($MN)
Table 47 Global Veterinary Oncology Market Outlook, By Precision Oncology (2023–2034) ($MN)
Table 48 Global Veterinary Oncology Market Outlook, By End User (2023–2034) ($MN)
Table 49 Global Veterinary Oncology Market Outlook, By Veterinary Hospitals (2023–2034) ($MN)
Table 50 Global Veterinary Oncology Market Outlook, By Veterinary Clinics (2023–2034) ($MN)
Table 51 Global Veterinary Oncology Market Outlook, By Veterinary Diagnostic Laboratories (2023–2034) ($MN)
Table 52 Global Veterinary Oncology Market Outlook, By Veterinary Academic and Research Institutes (2023–2034) ($MN)
Table 53 Global Veterinary Oncology Market Outlook, By Distribution Channel (2023–2034) ($MN)
Table 54 Global Veterinary Oncology Market Outlook, By Hospital Pharmacies (2023–2034) ($MN)
Table 55 Global Veterinary Oncology Market Outlook, By Retail Pharmacies (2023–2034) ($MN)
Table 56 Global Veterinary Oncology Market Outlook, By Online Pharmacies (2023–2034) ($MN)
Table 57 Global Veterinary Oncology Market Outlook, By Direct Sales (2023–2034) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.
Table 1 Global Veterinary Oncology Market Outlook, By Region (2023–2034) ($MN)
Table 2 Global Veterinary Oncology Market Outlook, By Animal Type (2023–2034) ($MN)
Table 3 Global Veterinary Oncology Market Outlook, By Dogs (2023–2034) ($MN)
Table 4 Global Veterinary Oncology Market Outlook, By Cats (2023–2034) ($MN)
Table 5 Global Veterinary Oncology Market Outlook, By Horses (2023–2034) ($MN)
Table 6 Global Veterinary Oncology Market Outlook, By Other Companion Animals (2023–2034) ($MN)
Table 7 Global Veterinary Oncology Market Outlook, By Cancer Type (2023–2034) ($MN)
Table 8 Global Veterinary Oncology Market Outlook, By Lymphoma (2023–2034) ($MN)
Table 9 Global Veterinary Oncology Market Outlook, By Mast Cell Cancer (2023–2034) ($MN)
Table 10 Global Veterinary Oncology Market Outlook, By Osteosarcoma (2023–2034) ($MN)
Table 11 Global Veterinary Oncology Market Outlook, By Mammary Gland Tumors (2023–2034) ($MN)
Table 12 Global Veterinary Oncology Market Outlook, By Melanoma (2023–2034) ($MN)
Table 13 Global Veterinary Oncology Market Outlook, By Soft Tissue Sarcoma (2023–2034) ($MN)
Table 14 Global Veterinary Oncology Market Outlook, By Hemangiosarcoma (2023–2034) ($MN)
Table 15 Global Veterinary Oncology Market Outlook, By Squamous Cell Carcinoma (2023–2034) ($MN)
Table 16 Global Veterinary Oncology Market Outlook, By Transitional Cell Carcinoma (2023–2034) ($MN)
Table 17 Global Veterinary Oncology Market Outlook, By Other Cancer Types (2023–2034) ($MN)
Table 18 Global Veterinary Oncology Market Outlook, By Diagnosis (2023–2034) ($MN)
Table 19 Global Veterinary Oncology Market Outlook, By Imaging (2023–2034) ($MN)
Table 20 Global Veterinary Oncology Market Outlook, By X-ray (2023–2034) ($MN)
Table 21 Global Veterinary Oncology Market Outlook, By Ultrasound (2023–2034) ($MN)
Table 22 Global Veterinary Oncology Market Outlook, By Computed Tomography (CT) (2023–2034) ($MN)
Table 23 Global Veterinary Oncology Market Outlook, By Magnetic Resonance Imaging (MRI) (2023–2034) ($MN)
Table 24 Global Veterinary Oncology Market Outlook, By Positron Emission Tomography (PET) (2023–2034) ($MN)
Table 25 Global Veterinary Oncology Market Outlook, By Biopsy and Histopathology (2023–2034) ($MN)
Table 26 Global Veterinary Oncology Market Outlook, By Cytology (2023–2034) ($MN)
Table 27 Global Veterinary Oncology Market Outlook, By Molecular Diagnostics (2023–2034) ($MN)
Table 28 Global Veterinary Oncology Market Outlook, By Immunohistochemistry (2023–2034) ($MN)
Table 29 Global Veterinary Oncology Market Outlook, By Laboratory Tests (2023–2034) ($MN)
Table 30 Global Veterinary Oncology Market Outlook, By Other Diagnostic Methods (2023–2034) ($MN)
Table 31 Global Veterinary Oncology Market Outlook, By Treatment Type (2023–2034) ($MN)
Table 32 Global Veterinary Oncology Market Outlook, By Chemotherapy (2023–2034) ($MN)
Table 33 Global Veterinary Oncology Market Outlook, By Surgery (2023–2034) ($MN)
Table 34 Global Veterinary Oncology Market Outlook, By Radiation Therapy (2023–2034) ($MN)
Table 35 Global Veterinary Oncology Market Outlook, By Immunotherapy (2023–2034) ($MN)
Table 36 Global Veterinary Oncology Market Outlook, By Targeted Therapy (2023–2034) ($MN)
Table 37 Global Veterinary Oncology Market Outlook, By Combination Therapy (2023–2034) ($MN)
Table 38 Global Veterinary Oncology Market Outlook, By Palliative Care (2023–2034) ($MN)
Table 39 Global Veterinary Oncology Market Outlook, By Route of Administration (2023–2034) ($MN)
Table 40 Global Veterinary Oncology Market Outlook, By Oral (2023–2034) ($MN)
Table 41 Global Veterinary Oncology Market Outlook, By Injectable (2023–2034) ($MN)
Table 42 Global Veterinary Oncology Market Outlook, By Topical (2023–2034) ($MN)
Table 43 Global Veterinary Oncology Market Outlook, By Therapy (2023–2034) ($MN)
Table 44 Global Veterinary Oncology Market Outlook, By Drug Therapy (2023–2034) ($MN)
Table 45 Global Veterinary Oncology Market Outlook, By Surgical Oncology (2023–2034) ($MN)
Table 46 Global Veterinary Oncology Market Outlook, By Radiation Oncology (2023–2034) ($MN)
Table 47 Global Veterinary Oncology Market Outlook, By Precision Oncology (2023–2034) ($MN)
Table 48 Global Veterinary Oncology Market Outlook, By End User (2023–2034) ($MN)
Table 49 Global Veterinary Oncology Market Outlook, By Veterinary Hospitals (2023–2034) ($MN)
Table 50 Global Veterinary Oncology Market Outlook, By Veterinary Clinics (2023–2034) ($MN)
Table 51 Global Veterinary Oncology Market Outlook, By Veterinary Diagnostic Laboratories (2023–2034) ($MN)
Table 52 Global Veterinary Oncology Market Outlook, By Veterinary Academic and Research Institutes (2023–2034) ($MN)
Table 53 Global Veterinary Oncology Market Outlook, By Distribution Channel (2023–2034) ($MN)
Table 54 Global Veterinary Oncology Market Outlook, By Hospital Pharmacies (2023–2034) ($MN)
Table 55 Global Veterinary Oncology Market Outlook, By Retail Pharmacies (2023–2034) ($MN)
Table 56 Global Veterinary Oncology Market Outlook, By Online Pharmacies (2023–2034) ($MN)
Table 57 Global Veterinary Oncology Market Outlook, By Direct Sales (2023–2034) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.
More Publications
Global Veterinary Diagnostics Market Outlook (2014-2022)
US$ 4,150.00
July 2015
91 pages
Animal Feed Antibiotics Market Forecasts to 2030 – Global Analysis By Product Type (Tetracyclines, Penicillins, Sulfonamides, Macrolides, Aminoglycosides, Cephalosporins, Fluoroquinolones and Lincosamides), Formulation (Premixes, Powders, Liquids and Other Formulations), Livestock, Sales Channel and By Geography
US$ 4,150.00
February 2025
150 pages
